We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+34.21%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$8.57B
AUM Growth
+$1.33B
Cap. Flow
+$552M
Cap. Flow %
6.44%
Top 10 Hldgs %
58.85%
Holding
53
New
11
Increased
15
Reduced
3
Closed
7

Top Buys

Rank Stock Value
1
ARWR icon
Arrowhead Research
ARWR
+$238M
2
VERA icon
Vera Therapeutics
VERA
+$188M
3
ALPN
Alpine Immune Sciences Inc
ALPN
+$170M
4
VKTX icon
Viking Therapeutics
VKTX
+$160M
5
MGNX icon
MacroGenics
MGNX
+$93M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$287M
2
CBAY
Cymabay Therapeutics
CBAY
+$262M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$135M
4
GPCR icon
Structure Therapeutics
GPCR
+$95.1M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$39.6M

Sector Composition

Rank Sector Weight
1 Healthcare 94.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$25.9B
$657M 7.66%
2,858,888
– –
APLS
2
DELISTED
Apellis Pharmaceuticals
APLS
$653M 7.62%
11,111,111
– –
ASND icon
3
Ascendis Pharma A/S
ASND
$16.6B
$600M 6.99%
3,966,666
+211,111
+6% +$30.1M
SRPT icon
4
Sarepta Therapeutics
SRPT
$1.64B
$562M 6.56%
4,344,444
– –
MDGL icon
5
Madrigal Pharmaceuticals
MDGL
$12.4B
$519M 6.06%
1,944,444
+55,556
+3% +$13.1M
ARGX icon
6
argenx
ARGX
$54.9B
$488M 5.69%
1,238,467
+3,900
+0.3% +$1.51M
KRYS icon
7
Krystal Biotech
KRYS
$10.6B
$455M 5.3%
2,555,555
-10,000
-0.4% -$1.39M
XBI icon
8
State Street SPDR S&P Biotech ETF
XBI
$9.97B
$408M 4.76%
4,300,000
-144,444
-3% -$13.4M
BMRN icon
9
BioMarin Pharmaceuticals
BMRN
$11.9B
$381M 4.45%
4,365,000
+65,000
+2% +$5.82M
FOLD
10
DELISTED
Amicus Therapeutics
FOLD
$323M 3.76%
27,400,000
– –
CERE
11
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$319M 3.73%
7,555,555
– –
VKTX icon
12
Viking Therapeutics
VKTX
$3.86B
$294M 3.43%
+3,590,000
New +$160M
ARWR icon
13
Arrowhead Research
ARWR
$11.9B
$245M 2.85%
8,555,555
+7,425,555
+657% +$238M
XENE icon
14
Xenon Pharmaceuticals
XENE
$6.15B
$244M 2.85%
5,666,666
– –
ALPN
15
DELISTED
Alpine Immune Sciences Inc
ALPN
$229M 2.67%
+5,775,000
New +$170M
VERA icon
16
Vera Therapeutics
VERA
$2.31B
$227M 2.65%
+5,265,000
New +$188M
IOVA icon
17
Iovance Biotherapeutics
IOVA
$2.03B
$173M 2.02%
11,700,000
+5,000,000
+75% +$58.2M
ITCI
18
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$171M 2%
2,475,000
+219,445
+10% +$15.1M
KYMR icon
19
Kymera Therapeutics
KYMR
$8.6B
$156M 1.82%
3,888,888
+113,888
+3% +$4.07M
RNAM
20
DELISTED
Avidity Biosciences
RNAM
$149M 1.73%
5,825,000
+3,315,000
+132% +$52M
MLTX icon
21
MoonLake Immunotherapeutics
MLTX
$1.58B
$130M 1.51%
2,580,000
– –
SNDX icon
22
Syndax Pharmaceuticals
SNDX
$1.68B
$100M 1.17%
4,222,222
– –
MGNX icon
23
MacroGenics
MGNX
$235M
$90.5M 1.06%
+6,150,000
New +$93M
KURA icon
24
Kura Oncology
KURA
$785M
$82.1M 0.96%
3,850,000
+870,000
+29% +$16.9M
AUTL
25
Autolus Therapeutics
AUTL
$378M
$78.8M 0.92%
+12,345,678
New +$77M
1
2 3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q1 2024 Portfolio in Review

As of Q1 2024, Avoro Capital Advisors held 53 positions worth $8.57B, up 18% from $7.24B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Avoro Capital Advisors deployed $552M of net new capital in Q1 2024, opening 11 new positions and adding to 15 existing holdings. Its largest new stake was Vera Therapeutics: 5,265,000 shares worth $227M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $135M trimmed.

  • Avoro Capital Advisors's largest Q1 2024 buy was Vera Therapeutics: 5,265,000 shares worth $227M.
  • Avoro Capital Advisors added most to Arrowhead Research in Q1 2024, an estimated $238M increase.
  • Avoro Capital Advisors's biggest Q1 2024 reduction was Alnylam Pharmaceuticals, cutting an estimated $135M.
  • Avoro Capital Advisors fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $287M.
  • Avoro Capital Advisors's ten largest holdings make up 59% of its $8.57B portfolio in Q1 2024.
  • Avoro Capital Advisors opened 11 new positions and closed 7 in Q1 2024.
  • Avoro Capital Advisors's portfolio value rose 18% quarter-over-quarter to $8.57B.

Based on Avoro Capital Advisors's 13F filing for Q1 2024, filed 15 May 2024.